Genomics In-Depth Focus 2019
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
List view / Grid view
In this In-Depth Focus are articles on how genomics could revolutionise clinical treatment and an insight into the promise and pitfalls of using CRISPR.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
A study has used CRISPR-Cas9 to treat obesity and type 2 diabetes symptoms in mice, highlighting the potential use in humans.
Researchers have created a new technique for activating genes using bacteria which could have therapeutic uses.
A tumour-targeted CRISPR gene editing system encapsulated in a nanogel could halt the growth of triple-negative breast cancer.
A new technique called ‘ubiquitin clipping’ has been created which could aid proteomics research and the development of new drugs for ubiquitination.
A research team have used genome editing to correct two of the mutations that cause cystic fibrosis.
Researchers have successfully used a no-cut CRISPR gene editing technique as a therapy for muscular dystrophy in mice models.
A study has used new synthetic lipids to deliver CRISPR gene editing tools into cells with up to 90 percent efficiency.
A research team have developed a new CRISPR platform called RESCUE (RNA Editing for Specific C to U Exchange).
Researchers have generated images of CRISPR-Cas9 gene editing for the first time, enabling improvement of the technique.
New method for directed evolution could improve gene therapies and generic drug development.
A new study has used combined therapies to eliminate HIV from mice models, providing potential future cures.
A study has reported that genes delivered to rhesus monkeys are still being expressed four years later.
Researchers announce positive pre-clinical results for two sickle cell disease treatment strategies.